Product
AND019
Aliases
AND019 PO QD
1 clinical trial
1 indication
Indication
Breast CancerClinical trial
A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2026-05-01